Drug Search Results
More Filters [+]

NaNots - NaNotics

Alternative Names: NaNots - NaNotics
Latest Update: None
Latest Update Note: None

Product Description

The company is advancing a pipeline of NaNots targeting oncology and inflammatory markers associated with multiple diseases that present substantial unmet medical needs. Additionally, they have announced research collaborations with Mass General Cancer Clinic, situated within Mass General Hospital, and Mayo Clinic to further enhance their therapies for specific oncology targets. (Sourced from: https://www.newswire.ca/news-releases/lifespan-vision-ventures-invests-in-nanotics-845938828.html)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: NaNotics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NaNots - NaNotics

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Hematological Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title